catalyst, call calendars could make sense. >> mike? >> i think looking at stock s substitution strategies is the way to play it. >> our time has expired. for more options, go to our . my mission is simple. to make you money. i'm here to level the playing field for all investors. there's always a bull mark somewhere and i promise to help you find it. "mad money" starts now. hey, i'm cramerment welcome to "mad money." welcome to krempblth i want to make friends, i don't want any more days like today. my job is not just to educate you, but to help you make money. sell in may and miss a huge rally? can we make that the catchphrase next year please now we got a

terrific 3% gain, despite today's hideous pullback. s&p dropped 1.43%. nasdaq down 1 point or 1%. i got to tell you something -- the house of pain! you know we never bought into all that sell in may nonsense. i ridicule it every day here. i hope you didn't either. come to think of it, it would have been a great day to sell the last week in may, but june, i got to tell you something, when i look at next week's business, i got a little trepidation about how things are going to shake out. at long last after five months of improving the economy, we are in what i hate, a bizarro world. where not for me, for many, good news is bad news. that's why the hedge funds are so afraid of the federal reserve sending its economic stimulus anything that smacks the economy will send all stocks tumbling. we simply need to be there when the hedge funds throw them away at once.

there are many stocks that do, indeed, thrive in this environment. what are the right ones? how about the stocks that provided we get some lift in the rest of the world, better earnings in the second half of the year the banks, the industrials, all of which can bounce after they are hammered, lower the whole market on strong economic data. what do the wrong once, this is tough, the stock that have higher yields, because strong economic data send up interest rates. when we get higher rates, that nullifies higher rate bonds. so utility, consumer package goods. remember i told you about that procter & gamble, master limited partnerships. real estate trusts. they can be deadly here, just deadly. sell, se sell! of course. look, i know you don't feel like this after down 200, but we could have some ideal combination of slower but still good growth in the united nations. will keep interest rates in check, stronger growth, particularly overseas in china and europe. i'm not banking on that anymore.

we have to wait. how long will we have to wait if we get that ideal combination? we will find out. what's your game plan? on sunday night, of course, you won't be reacting to it monday morning, you can get a key number out of chosen the nonmanufacturing pmi. i expect it to be alas disappointing. like everything else from china. what else is new? i will say if we get one good number from china, the men ral stocks are so low, they can rock it. we have euro zone, to be honest, all you see sheer a number as bad as the last one. would that be too much to ask? and if we do, we will catch a rally, both here and there, that's only just as bad as we expected. tuesday, we can shift the store, because this is all macro-day. tuesday, dollar general before the opening. last time we talked how they are showing you the rich, indeed, are spending like mad. what we have in america is a barbell economy. it's the great middle class

that's still being squeezed. sure, we learned consumer confidence is up. it translates to spending at target, walmart, j.c. penney i count on being how people are doing. the dar stores, though, they have been benefitting from the explosion that other people use food stamps. so i expect a good number from dollar general. we get a bunch of industrial tech companies, that are held by most investment banks every year during the first week of june. conference, conference, conference, i'm paying attention to the ones i always did, which is the banc of america, merrill lynch and the j.p. morgan industry conference the industrials. the companies presenting these shindigs will do best in the second half as business improves and revenues flow to these sale star business, alas, we got a real problem. i mean, tuesday? tuesday evening? dallas fed president richard fisher speaks on monetary policy in toronto.

fisher is a great guy. he's known as a real hawk, which means every time he opens his mouth, we expect him to say the feds will be less accommodative. this could be a nightmare speech for the bulls. be prepared for the blowback wednesday from fisher's speech tuesday night in toronto. two companies that i followed for a long time, brown tomorrow, they report on wednesday. i think the first one, should deliver a very good number, but, see in this new world, it might not be good enough as brown foreman is the kind of consumer staple stock this market has durn turned on t. old dress barn and charming shops, it's quietly moved to above 20. of that rally, i said, be careful, we see $18 real fast if it does. we got the adp, spare me on this one. the adp employment number wednesday morning. many people believe this is a good precursor, trying to fog figure out what the nonfarm payroll number. i'm going to suggest you ignore this number entirely and anybody who reports on it.

it's just not worth it dwraerm. i got to tell you, i have been tracking this thing. it is, you know what it is? it's a figure full of sound and fury signifying absolutely nothing. sorry. we got to stop treating this thing as important at all. i'm on a mission about that. anyway, oh, thursday, man, unbelievable. thursday is philly fed president charles plosser. he's speaking in boston. he's like a short-seller's dream. he's worse than dallas fed fisher, when he speaks. because when it comes to his impact on stock, let's just say he has been worried about infrustration forever. so we will be on full taper watch. not tapers like those weird animals tapir. taper like tapering off the fed bond buying program and perhaps selling them. egads. it doesn't matter he has been wrong about his view for ages. it doesn't matter other than

housing we aren't seeing that much strength in the economy just yet. who would ever let facts like these get in the way of a solid negative story? certainly not charles plosse. so be prepared for its 8:00 a.m. talk to send the market lower. he just feels it's his duty to be our own country's jean-claude, the european central bank meeting. it's thursday, touché, wouldn't it be great if they rolled back that moronic trade they put through. i think europe is bottoming. it's not enough. we need growth! finally, friday's employment numbers, the consensus is 170,000 job created. as much as you and i would love to see as many jobs as possible, we like people to go to work, one that comes in north of consensus, let's say 200,000 jobs, that will slam the bond

markets, which will, inturn, slam the bond market. when the smoke clears, we should circle back to the companies that told good stories at the conferences earlier in the week as well as the banks, which do incrediblybell well when rates rise. however, if we get a weaker number, do you know what the market can actually go higher? here's the bottom lean. as we saw today, we had a consumer confidence number, strong numbers in the chicago business report. the markets sold off on the strong economic news. you know what, that is exactly how it's going to be going forward until interest rates go higher or the economic news gets sluggish. don't worry, bad news is god news moment. it's the price we have to pay when the economy at last gets better than it used to be. let's go to michael in new jersey, please. michael. >> boo-yah, professor. >> oh, man, i didn't know i had tenure. what are you up to garden stater? >> caller: just one question

thely on's gate entertain -- lie on's gate -- lion's gate entertainment. >> you are late to the party on this everyone thought this happens in "hunger games." it's god a gaville things. -- gazillion things. let's go to matt in illinois. >> caller: hey, jim, a i'd like to give you a big blackhawk boo-yah. >> mojo boo-yah. the penguins are, wow, go ahead. >> caller: i got into sony when it hit $10, with all the act vis investor news threatening to push them up. should i take my profit around run? >> i'd wait until monday. i think dan logan is making good noise at sony. they've hired banks. let half run. you are playing with the other house's money. nick. >> caller: boo-yah, jim, from orange county, california.

>> love it, beautiful area. i lived in my car there. it's great weather. >> caller: my question today is about barwick rolled, gold prices in general.l has gold bottomed? >> actually yes, my go to gold guy said the miners are probably washed out. we don't like those stocks. it costs too much money to find gold. strong economic news. now the market sells off. good news is sell, sell, sell, bad news, that's what we saw today. until interest rates go higher, it's the price we have to pay for things actually finally getting better in this country. "mad money" will be right back. . come you can up, health class, tonight, cramer is looking deep into the medical industry. first up, a company with a brand if you way to battle on the front lines of the cancer fight. and later, beneficial breakup? plenty of companies have already proven that splitting up businesses can be a big win for

shareholders. now, cramer spotted the next stock that could be ready to tap into some hidden value by unlocking america's energy potential. plus, it's electric. cramer hops behind the wheel for a test drive of tesla. while the drive is electrifying, it's his take on the stock that can leave you truly shocked. stick around. . >> here's my take. profits are the mother's milk of

stock. you got to grow the pie larger for everybody. free market capitalism is the best path to pros period of time. this is "the kudlow report." i've nev er seen before. this ge jet engine can understand 5,000 data samples per second. which is good for business. because planes use less fuel, spend less time on the ground and more time in the air. suddenly, faraway places don't seem so...far away. ♪ that's not much, you think. except it's 2% every year. go to e-trade and find out how much our advice and guidance costs. spoiler alert: it's low. it's guidance on your terms, not ours. e-trade. less for us. more for you.

lets you talk face-to-face and share whatever's on your screen. blackberry z10 with bbm video. built to keep you moving. see it in action at blackberry.com/z10

>> today was one of the most important conference, the annual american society of clinical oncology. we all call it asco.

it runs until tuesday. in the spirit of asco. cancer people strut their stuff and present their meaningful trial data. i want to tell you about a new cancer-fighting technique. probably not on your radar screen. if we hadn't been working on this, i wouldn't have heard about it. it's cell dex therapeutics. it's $12 and change, small $1 billion market cap. so, therefore, right in the sweet spot. cell dex has been on a tear. i put that out there, i want you to know, it's not like we are new to this it's on very strong data. you know i never like to chase stocks, never do on "mad money." this name, although it's had a monumental move, i think is one of the rare cases where the stock could have a lot more room to run. the reason? celldex is doing gril brilliant work in the oncology yumplts it's known as cancer

immunotherapy. these are trugs that use the immune system to target and destroy cancer cells. now, this is a relatively novel approach to treating cancer. it will be a big them at the conference that started today t. way traditional chemotherapy radiation work is they carpet bomb your body with a toxic substance in the hope it destroys the cancer faster than it destroys healthy tissue. i always felt it was medieval. what celldex is different t. immunotherapy is it is target is the medical ekwifl ent of -- equivalent of a drone strike. the platform involves giving patients anti-bodies that have been engineered to make the cells in your immune system go on what i would regard as a search and destroy mission, looking for spec tumors. from the data we have seen so far, it works well without causing harmful side effects.

i'm not recommending the stock because celldex is working on an anti-cancer platform. the truth is, a lot of companies are working in this therapy space. celldex has done something else. the company is using these immunotherapies to combat the toughest, difficult to treat cancers out there. cancers, the current standard of care. at least in the clinical trials, celldex is extending people's lives dramatically. we will give you the names, they're number, initials, but it's called cdx011. it's a study for triple negative breast cancers that overexpress a particular geevenlt it's one of the most deadly forms of breast cancer out there. biotech companies haven't had much luck at all. it goes to phase 3. this is phase 2. patients being treated with cdx011 had a 32% response rate vs. a 13% response rate for patients getting same old chooem

chemotherapy. on average the people who didn't get the celldex drug survived five-and-a-half month. the patients with cdx 011 survived five months. they are beginning their accelerated approval study sometime later this year. they could potentially submit it for approval. the average drug takes seven years to get approved. ki they are working on a new drug, rindo for short as a front line treatment for glyoblastoma. it's an extremely rare lethal form of brain cancer. historically, people were diagnosed with the disease stwieved between 12 and 16 months. based on the trial data, that can increase it from 20.4 to 21.8 months. is huge. there is more data coming out at the end of the year. sellers could submit it for fda approval as soon as 2015.

not only is the fda giving this truck fast track. they've declared it an orphan drug. you and i, we really like orphan drug names. orphan designation is the reason why if they get approved, celldex could charge $80,000 to $100,000. insurers will pay. now, if just these two dwrug u drugs get approved, granted, that's a big f. celldex could generate close to a billion dollars annual revenues by 2018. if that happens the stock will be a heck of a lot more than it is right now. the market cap is worth a billion dollars. that's one of the reasons i'm sanctioning it after a big run, break my discipline, i know, maybe i'm being too bullish? suppose these two drugs gets approved and they generate $3 billion in sales, well, that amount of renew, they think they

can earn $160 per share. still good, that level of earnings? i can see it going from 13 to 20, a 53% gain. that's talking about the two biggest furtherest drugs along. they have a number of other projects in development that give the company multiple shots on goal. they have a drug to fight solid tumors, leukemia, lymphoma. they are early on along with a solid tumor vaccine in phrase 2. an orphan kidney condition that affects children and adults in phase 2. they have a recent capital raise. that gives them enough resources to last through 2015 the year their two big drugs come up for approval. right now the company is unpartnered, not splitting revenues. if they do decide split up, that could be a nice catalyst for the stock. celldex may have a lot of shots on goal and promising clinical trial data, but if the next

round isn't as good or the fda sends them packing, this stock could get eviscerated. company is releasing a lot of data at the end of the year. i think the news will be good based on what we seen so far. remember, speculation, inherently risky. on the other hand, if things go right, i will reap some enormous rewards here. celldex is a pioneer with a pair of drugs for hard to treat cancers that could by a proved if 2015. i leak the stock a lot. given that much it's run, there is no need for to you jump on top of it. you don't need to. i say, take your time. be patient. buy the stock into weakness. is how you would speculate wisely in celldex. after the break, i'll try to make you more money. coming up, beneficial breakup? plenty of companies have proven that splitting up businesses can be a big win for shareholders. now, cramer spotted the next stock that could be ready to tap into hidden value.

later, cramer's got more rising stars from the health care industry. next in line is a stock that's already more than doubled in 2013. but as it eyes a if you what i to diagnose disease, could it head even higher? all coming up on "mad money."

on a brutal day like today, just a pull ver iegz down s&p

both logged the one day worst drop since mid-april. done you wish you owned a stock that worked no matter what happened? wouldn't you like to push the share up simply through sheer force of will? guess what? it's possible. that's why i'm always pushing thooek these breakup stories because in a good breakup the ceo can catapult his or her stock higher with nothing more than a stroke of a pen. i'm not talking about some kind of financial outlook. not everybody can break up or spin off to higher levels. there are a lot of companies that can. we seen it over and over, businesses that get too big to spare the stock stops getting the respect from wall street t. big institution alimony managers, they like pure plays. they like clean categorys. they like it, the parts are worth more than the whole. so if a company can split up

into a pair of smaller operations that is simpler, cleaner to understand, you better believe just the announcement of this news will give the share price o-- owe a boost. tonight, tonight i got another one for you. well, it could be a multiple break of play. hallelujah! >> i'm talking about, occidental pretrollium. oxy. the big oil and gas producer you can follow along on my charitable trust. breakups have been huge winners, marathon, conoco, they have given us terrific gains since they split up one and two years ago respectively. remember i recommended hess in september. stock is up 28% t. company has begun to restructure itself and sell off the assets we want it to sell off. i think occidental can with a

lot more upside. the reason, occidental has been trying to get its act together. it underperformed lately. they have oil and gas assets all over the world, middle east, south america, as well as some important assets here at home, especially in texas' permean basin. monterey's shale. they gather, transport and store oil. that's like kinder morgan. that stock has been hammered. they have a fabulous commodity that i've always liked. i think these assets are too disparaged to work under the same roof. the god news here is that occidental's management recognizes the problem and they're planning to do something about it. right now, they're in the middle of a multi-stage strategic review. the problem is it's been put to the board by mid-summer. i think it's looking like the company will break up into two,

maybe three pieces, because the parts are way more than the whole, first step will be for occidental to spin off or outright sell its assets in the middle east or affect. i'm not kidding you, all the published, $20 billion. oxy can use that cash in a gigantic buyback. buy as much as 26%. then occidental assets in the americas. what we have been hearing here is management wants to split these two into two separate company, a value oriented on the permean basin, the permean is an old field. it is starting to pump more. all the new technologies, there ought to be a growth oriented operation centered around occidental's holdings in north american bakken shale. one is the monterey shale in california. we talk about the bakken all the time.

of course, it can really rival. but this monterey shale, it could be every bit as good and occidental is the number one player in this area by far. so how much would occidental be worth if it goes through this split and domestic dividend played and domestic growth played like the bakken in monterey. they fixed out the international business could be $22 a share. america's division could be worth $126 per share. add these together, subtract $7 net data on the balance sheechlt you get $141 per share. that 53% higher than where occidental is right now. those are the base case, fwhot the bull esche analysis, that puts the sum of the parts at $157 per share. this stock is $99 and change. okay, we don't know for sure what occidental will do.

that's where the opportunity comes in. it will bull higher. we will find out at the first stage the universal next conference call. gives you about seven weeks to build a position if you don't already have one. here's the bottom line, occidental petroleum, has good assets. it can't get the credit for its due, wall street at the moment are buried deeply in what is viewed as a big, sloppy hole. so i think it's terrific occidental ceo is talking about break up the business, possibly into three parts. plus, oxy is playing for the tr split and a stock that got hammered today as part of the decline in oil futures, which took all the oils down, including those that can rally on their own volition. like occidental petroleum. why don't i go to pat in california. >> caller: boo-yah, jim.

>> boo-yah, pat. >> >> caller: i got 9 parts of my 401 k, the only thing that's underperforming. what should i do? >> you know what, look. this is p miller. this is a great company. they have a hammer lock on the equipment business. it's up in '67. it's reported a bad quarter. it's gone higher then. i think 9% is fine. if you were to tell me 23%, i'd say you got to cut it back. you are fine with national oil embargo. hey, how about we go to bill in my home state of pennsylvania. bill. >> caller: hi, jim, bbb-boo-yah from devon. >> devon, horse country. let's talk. >> caller: energy has been flattering leak our phillies with the barium petroleum acquisition delayed the 52-week low hit yesterday and barnd's species article highly debumpgd. do you think the yield and energy is a buy?

>> remember, domenic brown is the hottest homeowner hitter in the league right now. wynne energy, we put out a deal, i'd love for the company to come on. i know the yield is high. we urge people not the panic. rerecognize there is a rotation out of these stocks. breaking up is really for the best these day, occidental petroleum, are you listening? they could be doing it. you get paid to buy on a pullback. oxy. stay with cramer. some people are never happy with the way things are. because they believe that things can always be better. we like those people. they think like us. introducing the best civic sedan yet.

made possible by honda. i got this. [thinking] is it that time? the son picks up the check? [thinking] i'm still working. he's retired. i hope he's saving. i hope he saved enough. who matters most to you says the most about you. at massmutual we're owned by our policyowners, and they matter most to us. whether you're just starting your 401(k) or you are ready for retirement, we'll help you get there. since aflac is helping with his expenses while he can't work, he can focus on his recovery. he doesn't have to worry so much about his mortgage, groceries, or even gas bills. kick! kick... feel it! feel it! feel it! nice work! ♪ you got it! you got it! yes! aflac's gonna help take care of his expenses. and us...we're gonna get him back in fighting shape. ♪ [ male announcer ] see what's happening behind the scenes

at ducktherapy.com. [ male announcer ] see what's happening behind the scenes lets you jump backwards and forwards in time to capture the perfect shot. blackberry z10 with time shift. built to keep you moving. see it in action at blackberry.com/z10

it is time! it's time for the lightning round. i tell you whether to buy, buy, buy, or sell, sell, sell. then the lightning round is over. are you ready, skeedaddy? matt in south carolina. >> caller: hi, jim. how are you doing? i have a question i want to get your opinion about. u.s. airways llc. and i did some research and stuff looked good for a long

time. how long does this stock take? >> remember, this was a merger are american airline, amr. it's an 18-month story t. market is headed down. this is an 18-month story. i like it. it want to go to fm in texas. >> hey, skeedaddy. >> yo, yo. >> caller: i like that current rating have you going there. >> thank you, partner. >> caller: how about opk, frost seems to keep -- >> look, i think you ought to buy i. i think bill frost is a genius. remember, it's a speculative stock. you buy a little here. if it comes in, that's a different story. new iowa. hugh. >> caller: thanks, jim. i have a lot of denver resources. >> it's been a big i huge win. you know what, i think that oil is coming down a little. maybe take something off the table. get a little gain in there. don't sell it all.

let's go to matt in alabama. matt. >> caller: hey, jim, moore university. i want to thank you for taking my call. >> you bet. >> caller: i like nps pharmaceutical. >> a good call. buy, buy, buy. chris in california. >> caller: boo-yah, chris ryan, i'm an undergraduate at the university of california, san diego. >> yes, great school. >> caller: we want to see you on your next college tour. investors are risking asset classes such as dividend paying stocks. what do you think about dper objection? >> it's okay to be honest, chris. i don't see a lot of upside to it. i would not, no, i mean, look, why, go buy honeywell. i mention that as another company that i think is a better run and is inexpensive. tom in south carolina.

>> caller: boo-yah from the big easy south klein. triquint. >> no, don't make the xoen component plachls you got to ring the register. triquint. i think those component plays are dangerous. let's go to roberto in oklahoma. >> caller: yes, jim, how are you? boo-yah. >> boo-yah. >> kelly: okay, jim. norman, oklahoma the question i want to ask you the company is in the 3d presenting sec roar. 3 the systems. what do you think about it? >> i like this, this is not my favorite. i think the 3d stocks are very vulnerable. let be careful. go to bill in florida. bill. >> hey, jim, from florida. how are you doing? i ha i have weyerhaeuser. i'm thinking to hang on to them. >> you should hang on to them. they're the fifth most

yesterday. that's ridiculous up for the charitable trust. i think pfizer is too expensive. i would not be a seller. brandon in georgia. >> caller: boo-yah, mr. cramer, how are you? >> real good. how are you? >> caller: awesome, thanks. i bought salesforce.com. >> they had yen problems and i still think it's good. remember it's a 4 for 1 split. if you take a look at where it was versus now, it's okay. i do think that salesforce will come back. that, ladies and gentlemen, is the conclusion of the lightning round!

>> go ahead, greg, you are up. >> caller: i'm here. >> good, why don't we talk stocks? >> okay. what the heck is going on here? >> play ball. >> this market is a lot like baseball. there is a machine on 1st. you would love to steal 2nd base. then you take your eye off the ball, suddenly, are you out. are you picked off. of course, we are investing in stocks with hype. we're not playing a ball game here. where is my baseball bat? i thought we kept the bat. where is that bat that has my face on it, the yellow bat. these stocks baibl became the baseball equivalent of trying to steal 2nd. i love that bat.

coming up, next in line, a stock that doubled more in 2013. as a new way to diagnose disease, could it head even higher? plus, it's electric. cramer hops behind the wheel of a test drive of tesla. while the drive is electrifying. it's his take on the stock that can leave you truly shocked. stick around. [ cows moo ] [ sizzling ] more rain... [ thunder rumbles ] ♪ [ male announcer ] when the world moves... futures move first. learn futures from experienced pros with dedicated chats and daily live webinars. and trade with papermoney to test-drive the market. ♪ all on thinkorswim. from td ameritrade.

[ kitt ] you know what's impressive? a talking car. but i'll tell you what impresses me. a talking train. this ge locomotive can tell you exactly where it is, what it's carrying, while using less fuel. delivering whatever the world needs, when it needs it. ♪ after all, what's the point of talking if you don't have something important to say?

. what does it mean to be a responsible investor? what does it mean to be prunet? right now, we're in a market where recklessness and responsibility have switched places with each other in some rear front seat back seat thing. conventional wisdom is your smart move is to buy bonds. as i said over and over again, bonds give you a culture return and bond prices are due for what i regard as a giant sell, sell, sell. if i do one thing to get you out of these bonds, more than

they've declined recently, that i will go lower. at least in this environment, the allegedly prudent owning bonds i regard as being reckless, dangerous. and if that's the case, maybe what most people think of as reckless investing, speculating high risk reward, maybe someone can become responsible. i advocate having one speculative stock. i tell you every friday t. small dollar names are exciting. they keep doing gains, provided, provided you mimic the risk. 3450e7b you you don't put as much in a spec vs. the portfolio. owning something speculative that pace off, it can be a handy way to help you beat the market. that's why tonight i want to introduce you to the tier lab corporation. symbol tar. i think tear. i was conscious if the accent makes it, tear, like this, tear

lab. a company that sells a laboratory on a chip platform, which analyzes the competition of tears in order to help doctors diagnose eye diseases on sight in the office, rather than have to send samples tout an external lab and wait until they get back to you. tear lab systems can diagnose your eye problem in the doctor's office. this is one of the smallest speculative companies i have recommend in a very long time with the market chalization just $300 million. plus the company has been on a geent tear, no pun intended, to $10 as of today a. 167% gain in six months. given the scale that's run, i missed it, end of the story. you know what, i wouldn't be telling you about a little stock like this unless i thought it had the potential for a lot more upside. see, tear lab is actually building a better mouse trap. their device is called the tear

lob osmolarity system. right now, it's used to diagnose dryize disease or ded. dry eye might not sound like a big deal. but there are between 20 and 40 million people who suffer from this condition in the u.s. alone. 5% are treated in part until tear lab came along, there was no way to test for ded at the doctor's office. you had to take a sample, send it to the lab. tear is the only one not designed in the lab, but at the doctor's care. it is 1,000 times smaller than other machines need. even better, you don't need to be a doctor to run the system. about a year-and-a-half ago, they granted them a cia waiver, which means your eye doctor can have a nurse or regular person operating the thing. dry eyes can be a serious condition. you are more likely to get eye infections which can lead to corneal nerve damage, which can

significantly compromise your vichlths restasis did 8 million in sales last year. just from dry eye, tear labs could only rake in $1.8 billion. once they get their systems, down the road this system can be used from everything from contact lens fitting to preand post-operative surgery, it has a razor blade business mile t. aiz razor is the tear lab desktop unit. razor played, disposable single use, microchip that costs $10 to $12 per procedure t. doctor boys the platform, every single time theyitis they need a disposable chip. starts to add up. the great thing about the razor blade model, your margins go higher and higher. we are seeing that with tear lab in 2012. that's what they may give to the cost of sales. they netted 21%. ferc of this year, 46%. more than double. not only that, this is a turbo

charge story. tear labs is expected to pose 300%. they should be turning a profit. the stock exploded higher after tear lab reported on may 13th. the company booked 388 ore itself analysts expect 234. management told us they had tripled their manufacturing class. the company is ramping up their sales force, too. i still think we're in the early innings of tear lab's growth story. they have a game changing eye device for the eye business. there is nothing else out there like it. at the moment a couple analysts have the stock. as it rises, it should attract wall street promotion machine, which will send it higher still. that's how these tiny speculative growth stocks expect to work. in 12 months, i can see it up 43% from where it is now. never forget tear lab is for speculation only. you only use limit orders. when you buy, you don't put too much money in relative to the

rest of your portfolio. it means you don't pay up at these levels. the market is coming down. the stock is a nickel and dime away from the 52-week high. it will give you a pullback. ideally, i'd like to see it get below $10 buck, i don't know if it will reach those lower levels. in a perfect world, we can buy low, sell high. styles when you deal with tear lab, you can only buy high and sell higher. this is not for the takent of heart. however, if you are willing to take a risk the company has a fabulous product and a better business model. i think that tear is far from being done. stick with cramer. we're cracking down on medicare fraud.

the healthcare law gives us powerful tools to fight it... to investigate it... ...prosecute it... and stop criminals. our senior medicare patrol volunteers... are teaching seniors across the country... ...to stop, spot, and report fraud. you can help. guard your medicare card. don't give out your card number over the phone. call to report any suspected fraud. we're cracking down on medicare fraud.

let's make medicare stronger for all of us.

. we got a cannes to test drive a tesla last night. take a look. let's lay some tunes [ music playing ] ♪ working so hard like a soldier ♪ can't afford a thing on the

street ♪ >> the verdict, all i can say is wow! i want one, even though i don't actually need a new car. i don't know if a tesla been affordable. it would have run out of power on the jersey garden turnpike. not where you want to pay $90 grand to take a parking spot in. the best, quiet, most powerful ride i ever had. no wonder consumer reports gave it the highest rate possible. does the stock deserve to be bought? a different question entirely. it roared from 80 miles per hour on i-95. tesla motors got hammered. the company might make 21,000 cars this year. but it wouldn't be profitable at this moment without government subsidy, something elon musk agreed with on "squawk on the street." i say pretty much.

musk is confident he can trim production. he says it will make the company profitable without the subsidies. i am reluctant to doubt musk. he makes a superior vehicle that is the envy of the industry. a product that's loved by environmentalists and car buffs alike. leak it or not, by the way, he has crushed the shorts with a profitable quarter in the promise of cheaper financing per vehicle. something that will grow the market far more quickly than the $90,000 price tag. here's the con91 drum for me. the product creates experience is publicly traded, then it's a serious candidate. they have to do home. tesla definitely fits that bill. on the other hand, i also always felt valuation matters. when i lost on valuation, i always lost. amazon, a superior product or is

tesla just a cold stock that has no business being above 100 or 50. steve jobs master of form and function sore he an incredible inrate issor that knows how to sell buzz and sell cars if 2013, while anile laizing -- annihilating the short sell. i can't teletell you to boy or short it either. it's the most dang ris short in years. buy the car t. stock, is even, i am doing something rare for cramerica, i'm punting. tesla is up to you. cold stocks can say cold for years. tesla is the ultimate in cars and the ultimate in cold stocks. stay with kramer. 200 point stock correction, just some profit taking? but irs doug schulman did see the white house and student loans drive up tuition. kudlow next up. can't work, he can focus on his recovery. he doesn't have to worry so much about his mortgage,

.

all right. there is a lot of talk there was a gigantic rebalancing at the end of the day. all well and good, i got to tell you we are morphocussed good

news is driving the market down and we are not getting enough bad news to stabilize him we had two good numbers today. be careful. this is a different kind of market. i'm jim cramer. i'll see you monday! the big story tonight, a strong sell-off to end the day, the week and the month on wall street. the dow fell 209 points, don't forget the month of may was still positive making six monthly gains in a row. today looked like late session profit-taking and maybe some rebalancing. the other big story, new trouble, new questions tonight for team obama on the irs scandal. it turns out, former irs chief doug schulman did meet with political operatives like stephanie cutter in at least some of his 157 white house visits. also, schulman's wife worked for a left wing group trying against campaign spending. these stories and much more